Entasis Therapeutics, Inc.
Waltham, MA
- UEI
- P6NKP5BBSUH3
- CAGE
- 7JD21
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 930 Winter St #1500, Waltham, MA 02451, USA
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$245,721 |
| FY2025 | -$13,919 |
Contract awards
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | $269,501 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Novel inhibitors of lpxc | Medical Command (Army) | $1,071,811 |
Similar vendors
About the company
Entasis Therapeutics Inc., a subsidiary of Innoviva, Inc., is developing a portfolio of innovative cures for serious drug resistant bacterial infections. It is a corporate, for-profit manufacturer of goods.
Entasis Therapeutics Inc. has received a $15.5 million definitive cost-no-fee contract from the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) to identify and develop a non-beta-lactam penicillin-binding protein inhibitor with broad spectrum activity against multidrug-resistant gram-negative ESKAPE pathogens. This work directly responds to a solicitation for proposals addressing therapeutics for antibiotic-resistant bacteria threats. Entasis will perform the research and development work in Waltham, Massachusetts from July 2020 through December 2022 with no subcontractors indicated, furthering NIAID's mission on infectious diseases. Additionally, Entasis Therapeutics Inc. has received a subcontract from the Trustees of Boston University. This subcontract supports research to discover novel, covalent non-beta-lactam penicillin-binding protein inhibitors with activity against multidrug-resistant Pseudomonas aeruginosa that are not degraded by beta-lactamases, with the goal of delivering a new class of antibiotic to treat serious gram-negative bacterial infections.
Entasis Therapeutics Inc. has also received a sub-grant from the Trustees of Boston University. This sub-grant funds research into the discovery of novel, covalent non-beta-lactam penicillin-binding protein inhibitors active against multidrug-resistant Pseudomonas aeruginosa and not degraded by beta-lactamases. The goal is to develop a novel class of antibiotics to treat serious gram-negative bacterial infections caused by critical pathogens identified by the CDC and WHO as top threats requiring research and development efforts.
Quick answers
Is Entasis Therapeutics, Inc. registered in SAM.gov?
Yes. Entasis Therapeutics, Inc.'s SAM.gov registration is active through June 10, 2027.
What is Entasis Therapeutics, Inc.'s CAGE code?
Entasis Therapeutics, Inc.'s CAGE code is 7JD21, and its Unique Entity ID (UEI) is P6NKP5BBSUH3.
What is Entasis Therapeutics, Inc.'s most recent federal award?
Entasis Therapeutics, Inc.'s most recent federal contract award is To identify and develop a non-beta-lactam PBP inhibitor (NBP) with broad spectrum of activity against MDR gram-negative… (75N93020C00017), from National Institute of Allergy and Infectious Diseases (NIH), on July 1, 2020.
On GovTribe
See Entasis Therapeutics, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors